Cartesian Therapeutics, Inc.
RNAC
$8.70
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 78.00K | 947.00K | 452.00K | 298.00K | 1.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 78.00K | 947.00K | 452.00K | 298.00K | 1.10M |
| Cost of Revenue | 19.46M | 14.69M | 13.80M | 14.87M | 14.67M |
| Gross Profit | -19.39M | -13.74M | -13.35M | -14.57M | -13.57M |
| SG&A Expenses | 7.11M | 8.20M | 7.72M | 7.24M | 8.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.58M | 22.89M | 21.52M | 22.11M | 22.99M |
| Operating Income | -26.50M | -21.94M | -21.07M | -21.81M | -21.89M |
| Income Before Tax | -39.18M | -101.77M | -35.90M | 15.89M | -17.71M |
| Income Tax Expenses | -- | -9.19M | -- | -- | -- |
| Earnings from Continuing Operations | -39.18M | -92.58M | -35.90M | 15.89M | -17.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.18M | -92.58M | -35.90M | 15.89M | -17.71M |
| EBIT | -26.50M | -21.94M | -21.07M | -21.81M | -21.89M |
| EBITDA | -25.88M | -21.33M | -20.46M | -21.22M | -20.73M |
| EPS Basic | -1.46 | -3.56 | -1.38 | 0.51 | -0.68 |
| Normalized Basic EPS | -0.59 | -0.48 | -0.46 | -0.47 | -0.44 |
| EPS Diluted | -1.46 | -3.56 | -1.38 | 0.50 | -0.68 |
| Normalized Diluted EPS | -0.59 | -0.48 | -0.46 | -0.46 | -0.44 |
| Average Basic Shares Outstanding | 26.86M | 26.01M | 26.00M | 25.98M | 25.90M |
| Average Diluted Shares Outstanding | 26.86M | 26.01M | 26.00M | 26.45M | 25.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |